SIRT2 and hepatocellular carcinoma: On the basis of our findings that inhibition of SIRT2 triggered degradation of FGL1 and enhanced T cell killing in vitro, we hypothesized that pharmacological inhibition of SIRT2 with AGK2 might also reduce FGL1 abundance and synergize with PD-L1 blockade to inhibit HCC growth in vivo.